Ugrás a tartalomra
Search

* Kérjük töltsön ki minden mezőt

Üzenet küldése
Search
2019. 10. 09. - 13:24 | Klinikai Tudomány Külső hírek

Az egyik felhasználónk, Prof. Giammaria Fiorentini új publikációja jelent meg

A teljes angol cikkhez kattintson ide
Hasnyálmirigy az emberi testben
Hasnyálmirigy az emberi testben

Gratulálunk a szerzőknek az új kutatáshoz!

Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients

Giammaria Fiorentini, MD1 , Donatella Sarti, PhD1, Virginia Casadei, MD1,
Carlo Milandri, MD2, Patrizia Dentico, MD2, Andrea Mambrini, MD3,
Roberto Nani, MD4, Caterina Fiorentini, MD5, and Stefano Guadagni, MD6

Abstract: Background: Pancreatic adenocarcinoma has a poor prognosis, resulting in a <10% survival rate at 5 years. Modulated electro-hyperthermia (mEHT) has been increasingly used for pancreatic cancer palliative care and therapy. Objective: To monitor the efficacy and safety of mEHT for the treatment of advanced pancreatic cancer. Methods: We collected data retrospectively on 106 patients affected by stage III-IV pancreatic adenocarcinoma. They were divided into 2 groups: patients who did not receive mEHT (no-mEHT) and patients who were treated with mEHT. We performed mEHT applying a power of 60 to 150 W for 40 to 90 minutes. The mEHT treatment was associated with chemotherapy and/or radiotherapy for 33 (84.6%) patients, whereas 6 (15.4%) patients received mEHT alone. The patients of the no-mEHT group received chemotherapy and/or radiotherapy in 55.2% of cases. Results: Median age of the sample was 65.3 years (range = 31-80 years). After 3 months of therapy, the mEHT group had partial response in 22/34 patients (64.7%), stable disease in 10/34 patients (29.4%), and progressive disease in 2/34 patients (8.3%). The no-mEHT group had partial response in 3/36 patients (8.3%), stable disease in 10/36 patients (27.8%), and progressive disease in 23/36 patients (34.3%). The median overall survival of the mEHT group was 18.0 months (range = 1.5-68.0 months) and 10.9 months (range = 0.4-55.4 months) for the non-mEHT group. Conclusions: mEHT may improve tumor response and survival of pancreatic cancer patients.